Search

Start Over Authors McKenna, Avery, author

2. Nadofaragene firadenovec and oportuzumab monatox for BCG-unresponsive, non-muscle invasive bladder cancer: effectiveness and value : final report

Author(s):
Atlas, Steven J., author
Touchette, Daniel R., author
Beinfeld, Molly, author
McKenna, Avery, author
Joshi, Mrinmayee, author
Chapman, Rick M., author
Pearson, Steven D., author
Rind, David M., author
Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, January 15, 2021
Subject(s):
Antibodies, Monoclonal -- therapeutic use
Urinary Bladder Neoplasms -- drug therapy
Genetic Vectors -- therapeutic use
United States

3. Observational real-world evidence update: prophylaxis of hereditary angioedema with Takhzyro and C1 inhibitors : effectiveness and value

Author(s):
Bloudek, Lisa, author
Jaksa, Ashley, author
McKenna, Avery, author
Carlson, Josh, author
Chen, Yilin, author
Patrick, Amanda, author
Campbell, Jon D., author
Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, August 24, 2021
Subject(s):
Angioedemas, Hereditary -- prevention & control
Complement C1 Inhibitor Protein
United States

6. Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: effectiveness and value : final evidence report

Author(s):
Lin, Grace A., author
Whittington, Melanie D., author
Nikitin, Dmitriy, author
Agboola, Foluso, author
McKenna, Avery, author
Herron-Smith, Serina, author
Pearson, Steven D., author
Campbell, Jonathan D., author
Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, February 21, 2023
Subject(s):
Antibodies, Monoclonal -- therapeutic use
Multiple Sclerosis, Relapsing-Remitting -- drug therapy
Treatment Outcome
Administration, Oral
United States

7. Special assessment of outpatient treatments for COVID-19: nirmatrelvir/ritonavir (Paxlovid) health-benefit price benchmark update

Author(s):
Whittington, Melanie D., author
Campbell, Jonathan D., author
Richardson, Marina, author
Nhan, Emily, author
McKenna, Avery, author
Agboola, Foluso, author
Pearson, Steven D., author
Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, December 20, 2022
Subject(s):
Ambulatory Care -- economics
Antiviral Agents -- economics
COVID-19 Drug Treatment
Drug Combinations
Drug Costs
Lactams
Leucine
Nitriles
Proline
Ritonavir
United States

8. AMX0035 and oral edaravone for amyotrophic lateral sclerosis: final evidence report

Author(s):
Makam, Anil N., author
Nikitin, Dmitriy, author
Richardson, Marina, author
Mohammed, Rasheed, author
McKenna, Avery, author
Pearson, Steven D., author
Rind, David M., author
Suh, Kangho, author
Carlson, Josh J., author
Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, September 13, 2022
Subject(s):
Amyotrophic Lateral Sclerosis -- drug therapy
Drug Therapy, Combination
Edaravone -- therapeutic use
Phenylbutyrates -- therapeutic use
United States

9. Novel agents to prevent chemotherapy-induced neutropenia and other myelosuppressive effects: revised evidence report

Author(s):
Tice, Jeffrey A., author
McKenna, Avery, author
Herce-Hagiwara, Belén, author
Moradi, Ashton, author
Pearson, Steven D., author
Ollendorf, Daniel A., author
Bloudek, Lisa, author
Carlson, Josh J., author
Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, March 17, 2022
Subject(s):
Antineoplastic Agents -- adverse effects
Chemotherapy-Induced Febrile Neutropenia -- drug therapy
Chemotherapy-Induced Febrile Neutropenia -- prevention & control
Neutropenia -- drug therapy
Neutropenia -- prevention & control
United States